← Eichor
Study identifier: NCT07321093 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

A Study of the Efficacy and Safety of BCD-281 in Patients With Relapsing-Remitting Multiple Sclerosis

Condition: Relapsing-remitting Multiple Sclerosis (RRMS)  ·  Sponsor: Biocad

PhasePhase 3
Planned participants292
Who can joinAll sexes, 18 Years to 55 Years
Healthy volunteersNo

About this study

The aim of this study is to compare the efficacy, safety profile, pharmacokinetics, pharmacodynamics, and immunogenicity of BCD-281 and the reference drug in subjects with relapsing multiple sclerosis.

This description comes directly from the study's public registry record.

Talk to the study team

Marina Krasnova  ·  +7 (812) 380 49 33  ·  krasnovam@biocad.ru

Always discuss trial participation with your own doctor first.

Locations (1)

LLC "Medis"Nizhny Novgorod, RussiaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07321093